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Blood Pressure Response Under
Chronic Antihypertensive Drug Therapy
The Role of Aortic Stiffness in the REASON (Preterax in
Regression of Arterial Stiffness in a Controlled Double-Blind) Study
Athanase Protogerou, MD,* Jacques Blacher, MD, PHD,† George S. Stergiou, MD,*
Apostolos Achimastos, MD,* Michel E. Safar, MD†
Athens, Greece; and Paris, France
Objectives We sought to evaluate the role of arterial stiffness on blood pressure (BP) response to drug treatment.
Background Increased arterial stiffness (pulse wave velocity [PWV]) is associated with increased systolic blood pressure
(SBP). Antihypertensive drug therapy achieves better control of diastolic blood pressure (DBP) than SBP does,
implying that increased PWV might be a predictor of the SBP response to treatment.
Methods The REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study is a randomized,
double-blind trial comparing atenolol versus perindopril/indapamide; 375 patients with hypertension, with BP
and PWV measurements at baseline and after 12 months of treatment, were divided into 3 tertiles according to
baseline PWV and included in a post-hoc analysis.
Results After 12 months of treatment, BP differed significantly between PWV tertiles (the third having the lowest re-
sponse, p  0.05). Factors related to smaller BP decline were low baseline BP, high baseline PWV, need for a
double dose of treatment, use of atenolol (only for SBP response), and age (only for DBP). Although DBP control
did not differ in the PWV tertiles, SBP control was significantly associated with PWV level (p  0.001) as well as
with the use of perindopril/indapamide (p  0.001). The predictive value of PWV on BP response was indepen-
dent of age, sex, mean BP, and cardiovascular risk factors.
Conclusions Baseline PWV is a significant predictor of BP response to antihypertensive treatment, independent from age, the
need for increasing drug dosage, and the presence of cardiovascular risk factors. Achievement of SBP control
appears to be influenced by aortic stiffness as well as by angiotensin-converting enzyme inhibition. (J Am Coll
Cardiol 2009;53:445–51) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.046m
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an management of hypertension, the degree of blood pres-
ure (BP) reduction, independent of the class of antihyper-
ensive agent, is the cornerstone of successful reduction of
ardiovascular (CV) risk (1). Current international guide-
ines (2) give various recommendations for optimization of
rug treatment, including: 1) the need for prompt initiation
f drug treatment, or not; 2) selection of the most appro-
riate antihypertensive agents; and 3) use of monotherapy or
ombination therapy, based on the level of BP and the
resence of other CV risk factors, target organ damage, or
oncomitant conditions. Based on the parameters above, all
ypertension societies emphasize the need for treatment
ndividualization. However, at present, there is no specific
rom the *Hypertension Center, Third Department of Medicine, Sotiria Hospital,
niversity of Athens, Athens, Greece; and the †Paris-Descartes University, Faculty of
edicine, Hôtel-Dieu Hospital, AP-HP, Diagnosis Center, Paris, France.s
Manuscript received February 11, 2008; revised manuscript received September 4,
008, accepted September 8, 2008.arker able to predict BP response to chronic antihyper-
ensive therapy.
See page 452
Carotid-femoral (CF) pulse wave velocity (PWV) is a
idely accepted marker of aortic (thoracic/abdominal)
tiffness and a marker of arterial wall alterations, inde-
endent from mean arterial pressure (MAP). The gradual
ncrease in PWV is a dominant trait of arterial wall aging,
hich is further accelerated by the effect of CV risk
actors (3). Aortic stiffness is an independent and stron-
er predictor of new onset hypertension and also of total
nd CV mortality in hypertensive subjects than BP itself
3,4). Finally, increased aortic stiffness is closely associ-
ted with increased systolic blood pressure (SBP), so it is
major determinant of hypertension phenotypes (isolatedystolic hypertension) (3). Antihypertensive drug therapy
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stolic blood pressure (DBP) (90
mm Hg) more often than SBP
(140 mm Hg), implying that
increased CF PWV might be a
predictor of the SBP response to
chronic antihypertensive drug
treatment. A recent observational
cross-sectional study in patients
treated for hypertension showed
that CF PWV is a significant pre-
dictor of uncontrolled BP inde-
pendently of MAP, the presence
of atherosclerosis, drug treatment,
and traditional CV risk factors (5).
The REASON (Preterax in
Regression of Arterial Stiffness
in a Controlled Double-Blind)
study (6–8) is a multicenter (13
ountries), randomized, double-blind, controlled, parallel
roup, 12-month trial, comparing the beta-blocker atenolol
ith the fixed-dose combination of the angiotensin-
onverting enzyme inhibitor (ACEI) perindopril with the
iuretic indapamide. The primary objective of the REA-
ON study was to investigate potential differences between
reatment arms regarding their effects on BP and CF PWV.
n the present post-hoc analysis, we specifically investigated
hether CF PWV, measured in hypertensive subjects be-
ore initiation of antihypertensive drug treatment (baseline,
0]): 1) was associated with the degree of treatment-induced
P reduction; and 2) was an independent predictor of
ffective BP control after 12 months of treatment.
ethods
tudy design. The design of the REASON study has
een described in detail elsewhere (7,8). In brief, 562
ubjects with uncomplicated hypertension and supine
BP 160 and 210 mm Hg and DBP 95 and 110
m Hg were recruited. Patients on antidiabetic, hypo-
holesterolemic, or other CV agents were excluded.
ritten consent was obtained from each patient, and the
rotocol was approved by the ethics committees of the
ndividual institutions of the study investigators.
After a 4-week placebo wash-out period, 469 subjects
ere randomly allocated to receive double-blind atenolol
50 mg once daily) or perindopril/indapamide (Per/Ind)
2/0.625 mg once daily) for 12 months. After 3 months of
reatment, if SBP remained 160 mm Hg and/or DBP
90 mm Hg, the drug dosage was doubled (dosage effect).
hen needed, drug dosage was progressively decreased over
to 15 days in order to avoid complications due to
eta-blockade.
The following hemodynamic investigations were in-
luded in the present study. Office BP was measured after
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
BMI  body mass index
BP  blood pressure
CF  carotid-femoral
CV  cardiovascular
DBP  diastolic blood
pressure
MAP  mean arterial
pressure
Per/Ind  perindopril/
indapamide
PWV  pulse wave velocity
SBP  systolic blood
pressure0 min rest in the supine position using a mercury sphyg- womanometer, just before study entry (M0) and after
2 months (M12). We previously showed that M0 and M12
P measurements were similar to office or ambulatory BP
easurements (6). CF PWV was determined at M0 and
12 by the automated device Complior (Colson, Paris,
rance), which allows online pulse wave recording and
alculation, as previously described (7,8). The reproducibil-
ty of Complior measurements has been previously reported
7,8).
From a total of 469 subjects, complete follow-up, includ-
ng valid BP and CF PWV measurements at both M0 and
12, was achieved in 375 subjects: 182 in the atenolol group
nd 193 in the Per/Ind group. Previous use of antihyper-
ensive drugs (before study entry) was reported in 269
ubjects. Treatment dosage was doubled in 63 subjects in
he atenolol group and 91 in the Per/Ind group.
tatistical analysis. In order to investigate the treatment-
nduced BP changes (BP12 to BP0) according to the level of
aseline aortic stiffness, the study population was divided
nto tertiles according to CF PWV0 (3 subgroups with 125
ubjects each were generated). Comparison of CV risk
actors and hemodynamic parameters at M0 and at M12
etween CF PWV0 tertiles was performed by using analysis
f variance (for quantitative parameters) and chi-square test
for categorical parameters). Because the main goal of the
resent study was to investigate the independent role of
ncreased CF PWV0 on the BP response, all factors con-
idered to be potential confounders of the BP response to
reatment (including CV risk factors, prior antihypertensive
rug treatment, group effect, dosage effect, and baseline BP)
ere subsequently introduced as covariates in the analysis of
ovariance to adjust for their effects.
Group effect was classified as 1  Per/Ind and 2 
tenolol. Dosage effect was classified as “dosage increase”
1 and “no dosage increase”  0. Previous use of
ntihypertensive drugs (yes, no), treatment arm (atenolol
r Per/Ind), the need for treatment titration during the
tudy, as well as the achievement of effective BP control
SBP 140 mm Hg and DBP 90 mm Hg) at M12 were
ompared among CF PWV0 subgroups (tertiles) using
hi-square tests. Linear regression analysis was applied in
rder to investigate the independent effect of CF PWV0
n the treatment-induced BP decline and the BP control
fter 12 months. All previously mentioned confounders
f BP response were entered into the regression models.
n order to identify multicollinearity, we assessed the
ariance inflation factor. Receiver-operator curve analysis
as applied to determine the ability of CF PWV0 to
redict adequate BP control after 12 months of treat-
ent. Unpaired t tests were used to assess differences
etween subjects with and without treatment titration. A
 0.05 was considered statistically significant. Analysis
as performed with SPSS version 13.0 statistical soft-
are (SPSS Inc., Chicago, Illinois).
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able 1 summarizes the differences in CV risk factors at
aseline among the tertiles of CF PWV0. Only age and
lasma creatinine increased significantly from the first to
hird tertiles. No significant differences were found regard-
ng sex, weight, height, body mass index (BMI), total
holesterol, plasma glucose, and smoking.
Table 2 describes the BP at M0 and M12 according to the
ertiles of CF PWV0. The MBP0 and SBP0 increased
ignificantly from the first to the third tertile. Similarly, after
2 months of treatment, BP (DBP12, SBP12, and MBP12)
ncreased significantly from the first to the third tertile.
Table 3 shows the achieved absolute (mm Hg) decline
BP12 to BP0) of SBP, DBP, and MBP after 12 months of
reatment according to the tertiles of CF PWV0 and after
djustment for age, sex, and the corresponding BP value at
0. Significantly larger declines in SBP, DBP, and MBP
ere observed in subjects with the lowest CF PWV0.
urther step-by-step adjustments for previous antihyperten-
ive drug treatment and CV risk factors (BMI, plasma
reatinine, glucose, and cholesterol) did not change these
ndings (data not shown). Identical results were found
hen the BP changes were expressed as relative (rather than
bsolute) changes from baseline ([BP12  BP0]/BP0) (data
ot shown).
Table 4 shows independent predictors of the achieved BP
eduction (BP12  BP0, mm Hg) of SBP and DBP after 12
onths of treatment. Variables entered in the model were
ge, history of antihypertensive therapy, drug and dosage
ffects, sex, smoking, and M0 values of BMI, plasma
lucose, plasma creatinine, total cholesterol, and CF PWV0.
ndependent predictors for a small reduction of SBP (mm
g) ([BP12 top BP0] takes negative values) were low SBP0,
he need for increased drug dosage (dosage effect), treat-
ent with atenolol (group effect), and high CF PWV0.
ndependent predictors of a small reduction in DBP (mm
g) were the need for increased drug dosage, low DBP0,
oung age, and high CF PWV0. Independent predictors of
ubject Characteristics at Baseline According to Tertiles of CF PW
Table 1 Subject Characteristics at Baseline According to Terti
Characteristic
First (5.5–10.65)
(n  125)
Age, yrs 46.0 (0.9)
Males, % 41 (32.8)
Weight, kg 77.9 (1.1)
Height, cm 169.3 (0.8)
Body mass index, kg/m2 27.1 (0.2)
Total cholesterol, mmol/l 5.60 (0.97)
Plasma glucose, mmol/l 5.31 (0.07)
Plasma creatinine, mmol/l 85.4 (1.2)
Smoking, n (%) 49 (39.2)
CF PWV0, m/s 9.3 (0.1)
alues are expressed as mean (standard error). Values in bold indicate significance. Analysis of va
CF PWV0 baseline carotid-femoral pulse wave velocity.ow MBP (mm Hg) reduction were the need for increased hrug dosage, low MBP0, and high CF PWV0. It should be
oted that in all 4 models, a high CF PWV0 was consis-
ently associated with a smaller BP response (SBP0, DBP0,
r MBP0).
No significant interaction was observed between CF
WV0 tertiles and drug group or drug dosage, regarding
heir effects on BP reduction. No significant change in
able 4 findings was observed after further adjustment for
aseline pulse rate or its change after 12 months. In
ddition, no collinearity was found between the indepen-
ent variables entered in any of the multivariate models.
Table 5 presents a comparison of the 3 subgroups of
articipants (tertiles of divided CF PWV0) regarding the
ntihypertensive drug treatment (previous use, group effect,
nd dosage effect) and the treatment-induced CF PWV
ecline during the study. The proportions of subjects with
rior use of antihypertensive drugs and treatment with
tenolol or Per/Ind were similar across the CF PWV0
ertiles. The proportion of subjects who received dosage
itration was significantly increased from the first to the
hird CF PWV0 tertile (p  0.001). The CF PWV
CF PWV0
Tertiles of CF PWV0 (m/s)
d (10.66–13.0)
(n  125)
Third (13.1–24.1)
(n  125) p Value
53.1 (0.9) 60.9 (0.9) 0.001
44 (35.8) 49 (39.5) 0.542
77.1 (1.1) 74.6 (1.1) 0.074
69.1 (0.8) 167.6 (0.8) 0.267
26.8 (0.2) 26.4 (0.2) 0.210
5.56 (0.88) 5.58 (0.96) 0.259
5.54 (0.07) 5.53 (0.07) 0.055
89.0 (1.2) 90.5 (1.2) 0.012
59 (47.2) 64 (51.2) 0.153
11.7 (0.1) 15.1 (0.1) <0.001
was used to compare quantitative variables and chi-square test to compare categorical variables.
BP, DBP, and MBP at Baseline and After 12onths of Treatment, Accord g to CF PWV0
Table 2 SBP, DBP, and MBP at Baseline and After 12Months of Treatment, According to CF PWV0
Tertiles of CF PWV0 (m/s)
First
(5.5–10.65)
(n  125)
Second
(10.66–13.0)
(n  125)
Third
(13.1–24.1)
(n  125) p Value
DBP0 97.3 (0.6) 99.8 (0.6) 98.1 (6.3) 0.012
SBP0 155.8 (1.1) 160.1 (1.1) 165.7 (1.1) <0.001
MBP0 116.8 (0.6) 119.9 (0.5) 120.6 (0.6) <0.001
HR0 72.4 (0.9) 72.6 (0.8) 72.7 (0.9) 0.970
DBP12 83.0 (0.7) 84.2 (0.7) 86.7 (0.8) 0.007
SBP12 137.0 (1.3) 140.0 (1.2) 143.5 (1.4) 0.007
MBP12 101.7 (0.8) 102.9 (0.8) 105.4 (0.9) 0.006
HR12 66.9 (0.9) 68.4 (0.8) 69.3 (0.9) 0.235
alues are expressed as mean (standard error). Values in bold indicate significance. Analysis of
ovariance was used to compare quantitative mean values. All parameters values are adjusted for
ge and sex.V0
les of
Secon
1CF PWV0 baseline carotid-femoral pulse wave velocity; DBP  diastolic blood pressure; HR
eart rate; MBP  mean blood pressure; SBP  systolic blood pressure.
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Arterial Stiffness and Response to Treatment February 3, 2009:445–51ecline after 12 months of treatment was larger in the
hird tertile (Table 5).
The proportion of subjects with effective BP control (SBP
140 mm Hg and DBP 90 mm Hg) significantly
ecreased from the first to the third CF PWV0 tertile (p 
.001) (Fig. 1). This difference among CF PWV0 tertiles
as observed exclusively regarding SBP control (p 0.001),
ut not DBP, and was found even in subjects with doubled
rug dosage (n  154) during follow-up (Fig. 1). Similar
esults were found in the total study population (n  375)
t 3-month (before treatment titration) or 12-month
ollow-up.
Figure 2 shows the ability of CF PWV0 to predict control
f SBP with treatment (SBP 140 mm Hg after 3 or 12
onths of treatment). CF PWV0 did not predict the DBP
ontrol (DBP 90 mm Hg) (data not shown).
iscussion
his article presents 3 major findings regarding the role of
ortic stiffness, assessed by CF PWV before initiation of
ntihypertensive drug treatment, on the long-term BP
lood Pressure Changes After 12 Months ofreatment Presented According to CF PWV0
Table 3 Blood Pressure Changes After 12 Months ofTreatment Presented According to CF PWV0
Tertiles of CF PWV0 (m/s)
First
(5.5–10.65)
(n  125)
Second
(10.66–13.0)
(n  125)
Third
(13.1–24.1)
(n  125) p Value
DBP 15.6 (0.8) 14.2 (0.7) 12.1 (0.7) 0.011
SBP 24.5 (1.3) 20.8 (1.2) 17.6 (1.3) 0.008
MBP 18.4 (0.9) 16.3 (0.8) 14.1 (0.9) 0.007
alues are expressed as mean (standard error) in mm Hg. Values in bold indicate significance.
esults are adjusted for age, sex, and the corresponding baseline blood pressure by analysis of
ovariance.
Abbreviations as in Table 2.
redictors of SBP and DBPecl ne After 12 Months of Treatment
Table 4 Predictors of SBP and DBPDecline After 12 Months of Treatment
BP Reduction
(BP12  BP0),
mm Hg Predictors p Value B
95% Confidence
Interval
SBP SBP0 <0.001 0.666 0.779 to0.553
Dosage effect <0.001 6.218 3.409 to 9.152
Group effect 0.001 4.647 1.799 to 7.134
CF PWV0 0.001 1.059 0.454 to 1.664
DBP Dosage effect <0.001 3.899 2.128 to 5.669
DBP0 <0.001 0.490 0.616 to 0.384
CF PWV0 0.019 0.441 0.074 to 0.807
Age 0.036 0.091 0.176 to0.006
MBP Dosage effect <0.001 4.789 2.837 to 6.741
MBP0 <0.001 0.593 0.738 to0.448
CF PWV0 0.003 0.596 0.201 to 0.990
ariables entered in the linear regression models: age, sex (male), body mass index, smoking, and
aseline (0) values of plasma glucose, plasma creatinine, total cholesterol, pulse wave velocity,
roup effect (1 perindopril/indapamide, 2 atenolol), dosage effect (1 dosage increase, 2
o dosage increase), previous use of antihypertensive drugs, and corresponding blood pressureh
BP) (systolic, diastolic, or mean). Values in bold indicate significance.
Abbreviations as in Table 2.esponse to antihypertensive drug treatment. First, the
ighest CF PWV0 tertile was associated with the smallest
P response to drug treatment and a greater need for drug
osage increase. Second, CF PWV0 was a highly significant
ndependent predictor of effective SBP control, but not of
BP, after 12 months of drug treatment. Third, these
esults were independent of age, baseline BP, previous
ntihypertensive drug therapy, drug class, and dosage effects
s well as traditional CV risk factors. Taken together, these
ndings suggest that PWV, which is an established marker
f the stiffness of central arteries, gives supplementary
nformation to those obtained from brachial BP measure-
ents, regarding the BP response to drug treatment.
In the REASON study, antihypertensive drug treatment
educed SBP, DBP, MBP, CF PWV, and presumably,
eripheral resistance, in both treatment arms (atenolol and
er/Ind) (6–8). The present analysis showed that in the
igh CF PWV0 tertile, there was a smaller decrease in
eripheral resistance, concluded from the MBP response,
ven after doubling the drug dosage (Tables 3 and 4). This
bservation suggests that large artery structural changes
eflect less reversible structural alterations at the level of the
rterioles, even after long-term antihypertensive drug treat-
ent. Thus, the present findings support the hypothesis of
common pathophysiologic pathway in hypertensive sub-
ects affecting both the macro- and the microcirculation.
The design of the REASON study, as well as the wide
ange of CF PWV0 (5.5 to 24.1 m/s) that was observed in
his population, has provided advantages and also difficulties
n interpreting the previously mentioned findings. First, the
ouble-blind design enabled comparison of a monotherapy
atenolol) versus a combination therapy (Per/Ind) as first-
ine drug treatment. This study feature was not jeopardized
y separating the population into tertiles of arterial stiffness.
hus, the present findings suggest that, in the presence of
ncreased aortic stiffness, inadequate BP response to anti-
omparison of Subgroups of ParticipantsTertile ) Divided by CF PWV0
Table 5 Comparison of Subgroups of Participants(Tertiles) Divided by CF PWV0
Tertiles of CF PWV0 (m/s)
First
(5.5–10.65)
(n  125)
Second
(10.66–13.0)
(n  125)
Third
(13.1–24.1)
(n  125) p Value
Previous use of
antihypertensive
drugs
70.4 70.4 74.4 NS
Group effect, % 50.4 46.4 48.8 NS
Dosage effect, % 25.6 40.8 52.8 <0.001
CF PWV12 to
PWV0, m/s
0.2 0.5 2.2 <0.001
ntihypertensive drug treatment refers to previous use of drugs; group effect refers to atenolol
ersus perindopril/indapamide; and dosage effect refers to dosage increase (chi-square test). CF
WV12 to PWV0 is the treatment-induced pulse wave velocity decline (as measured by analysis of
ovariance) during the study. Results did not change when pulse wave velocity (PWV) changes were
xpressed as relative change from baseline ([PWV12 to PWV0]/PWV0; data not shown). Values in
old indicate significance. Adjusted for age, sex, baseline MBP, and its change after 12 months of
reatment.
Abbreviations as in Table 2.ypertensive drug treatment (particularly regarding MBP)
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February 3, 2009:445–51 Arterial Stiffness and Response to Treatmentay be observed regardless of the use of monotherapy or
ombination therapy. However, the lack of an intensive
dd-on treatment strategy during the study (on top of the
nitial drug treatment) resulted in uncontrolled BP in almost
ne-half of the population, limiting the study conclusions
egarding the ability of CF PWV to predict the response of
P to a scenario closer to clinical practice. Another issue is
hat in the REASON study, office BP was estimated in the
1st                    2nd        
                CF PWV0 tert
0
10
20
30
40
50
60
70
P
a
ti
e
n
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%
)
Figure 1 Percentage of Patients* With Effective Blood Pressur
*Population with increased dosage (n  154), similar results were found in the w
after 3 months (i.e., before dosage increase) and at 12 months. CF PWV0  base
Figure 2 Aortic Stiffness Predicts Systolic Blood
Pressure Response After 12 Months of Treatment
Receiver-operator curve analysis evaluating the ability of pulse wave velocity at
baseline to predict the adequate control of systolic blood pressure (140 mm
Hg) after 12 months of drug treatment (area under curve 0.67, p  0.001,
95% confidence interval: 0.62 to 0.73).supine position. Therefore, cautious interpretation of these
esults is needed since PWV and baroreflex sensitivity are
nter-related and modulate postural changes of BP (9).
owever, in a subpopulation of the REASON study (n 
01), identical results have been reported using either
mbulatory BP or supine office BP readings (6), suggesting
hat the present results might be extrapolated to clinical
ractice.
The second major finding of this study was that when
articipants were classified into CF PWV0 tertiles, the
esponse of SBP differed from that of DBP. The SBP was
ncreased in parallel with increasing PWV, both at baseline
nd after 12 months of treatment. However, the situation
as different regarding DBP. Before treatment initiation,
BP was poorly associated with PWV tertiles and pre-
ented an inverse “U-shaped” relationship, as usually ob-
erved in isolated systolic hypertension in the elderly (Table
). However, after 12 months of treatment, DBP was
ignificantly and positively correlated with baseline PWV,
nd the smaller treatment-induced DBP decline corre-
ponded to the higher baseline PWV tertile (Tables 2 and
). These findings are in line with the theory that in subjects
lder than 50 years, and for a given cardiac function,
ncreased SBP is influenced mainly by increased arterial
tiffness and/or altered amplitude or timing of wave reflec-
ions; low DBP is modulated mainly by low vascular
esistance, but also by the increase of arterial stiffness. Since
he main determinants of aortic SBP and DBP differ (10),
t might be highly expected that in middle-aged subjects (as
s the REASON study population), aortic stiffness is a
etter predictor of effective SBP rather than DBP control
ith treatment. Indeed, these data showed that: 1) aortic
Diastolic blood pressure <90 mmHg 
(p=NS) 
Systolic blood pressure <140 mmHg 
and diastolic <90 mmHg (p<0.001) 
Systolic blood pressure <140 mmHg 
(p<0.001) 
   3rd
ntrol After 12 Months of Treatment
pulation (n 375)
rotid-femoral pulse wave velocity.       
iles 
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Arterial Stiffness and Response to Treatment February 3, 2009:445–51BP control; and 2) this predictive value is independent of
oth drug class and dosage.
Several aspects of the association between SBP and PWV
hould be considered. The principal finding of the REASON
tudy was that, for the same decrease in DBP and MBP, the
er/Ind combination decreased SBP significantly more than
tenolol did, although in both arms PWV was equally
ecreased (7,8). A previous analysis of a REASON sub-
roup (n 181) with measurements of central BP and wave
eflections (augmentation index) showed that the effect of
he Per/Ind combination on SBP was even more pro-
ounced at the level of the central (carotid artery, thoracic
orta) than the peripheral arteries and was associated with a
ignificant attenuation of wave reflections (not observed
ith atenolol) (7,8). Due to the limited number of subjects
ith complete follow-up regarding central BP measure-
ents (8,11), no subgroup analysis according to CF PWV0
ertiles was performed in the present study. However, the
esults of the REASON study were verified by the results of
larger epidemiologic study (CAFÉ [Conduit Artery Func-
ion Evaluation]) (12), and both studies suggest that the
ifference in SBP response to drug treatment is mainly
elated to changes in wave reflections rather than in aortic
tiffness. Moreover, since in both the REASON and CAFÉ
tudies, the beta-blocker atenolol was used in 1 treatment
rm, the observed results support the view that this partic-
lar drug reduces aortic SBP less than the other treatments.
In the present study, although aortic stiffness was reduced
ore in the highest tertile of CF PWV0 (Table 5), this
eduction was not associated with better control or a larger
BP decline, compared with the other tertiles (Fig. 1). This
nding might be explained by several observations that we
ave reported previously (8). First, in the entire REASON
tudy, the MAP decline was identical in the 2 treatment
rms, as confirmed by both office conventional and ambu-
atory BP measurements (11). In this respect, the change in
he distending pressure does not seem to modulate the
esults of the present analysis. Second, as we have previously
hown, within the first 6 months of treatment, the SBP
ecline was influenced mainly by the changes in wave
eflections (primarily their timing) (8). Third, according to
tudies on human biopsies, regression of structural arteriolar
hanges is known to begin at the end of the first year of
reatment (13), suggesting that this structural modification
orresponds to changes in reflection sites and results in
ignificant SBP decline (8,13,14).
Thus, the present findings suggest that, independently of
AP, time-dependent changes in wave reflections and
ascular remodeling occur and may interfere with 2 other
articularities. First, in some patients, irreversible structural
amage might occur at the arteriolar and/or large artery
evel, due to advanced stage and long-duration hyperten-
ion. Although the natural history of vascular aging (micro-
irculation vs. macrocirculation) (15) and the reversibility of samage have to be further elucidated, in the same line of
rgument, a smaller BP reduction is commonly observed in
atients with more severe cardiac hypertrophy. This obser-
ation is important to consider because the same subjects are
xpected to have more severe arterial stiffness and higher
entral BP levels. Second, the regression of structural
rteriolar changes observed with the ACEI is less pro-
ounced (or even absent) under beta-blockade (7,12,14),
ven in subjects with high CF PWV0, as suggested by the
ack of interaction between PWV tertiles and drug group.
The fact that CF PWV0 did not predict the effective
BP control, even in subjects with dose titration, might be
ttributed to the hypothesis that peripheral resistance is the
redominant mediator of DBP response to drug treatment.
nother plausible explanation is that the inverse U-shaped
attern of association between DBP and CF PWV0 level is
strong confounder. Indeed, there is a U-shaped pattern of
ssociation between CF PWV0 subgroups (tertiles) and
ffective DBP control rates (Fig. 1, blue bars).
linical implications. In the present study, we showed
hat vascular aging of the macrocirculation, as assessed by
F PWV, rather than age itself, is a major determinant of
he BP response to chronic antihypertensive drug treatment
nd that in the presence of increased large artery stiffness,
BP is more difficult to control than DBP. This effect was
ndependent from the BP level, antihypertensive agents, and
V risk factors. This result might be explained by the fact
hat aortic stiffness integrates most of the currently known
V risk factors as well as most of the described markers
elated to poor BP response to drug treatment (16). On the
ther hand, arterial stiffening per se is considered the cause
f isolated systolic hypertension and at the same time, may
e the cause of the poor response of SBP to drug treatment.
he development of de-stiffening drugs may provide the
asis for future research that will clarify this issue. In line
ith our previous cross-sectional study (6), these results
mply that effective BP control requires the concomitant
eduction of large artery stiffness, which is a major deter-
inant of SBP reduction. CF PWV may represent a useful
ndex to determine the need for more aggressive antihyper-
ensive therapy. This conclusion has already been suggested,
articularly in high-risk patients, such as those with end-
tage renal disease (14). The REASON study addressed this
uestion in subjects with relatively lower risk since a
eneficial effect may be obtained from early and optimal BP
ontrol.
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